Cash Flow Statement

Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

Xilio Therapeutics (XLO) Change in Accured Expenses (2024 - 2025)

Xilio Therapeutics (XLO) has disclosed Change in Accured Expenses for 2 consecutive years, with $928000.0 as the latest value for Q4 2025.

Quarterly Change in Accured Expenses rose 1191.76% to $928000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$979000.0 through Dec 2025, up 36.55% year-over-year, with the annual reading at -$979000.0 for FY2025, 36.55% up from the prior year.
Change in Accured Expenses hit $928000.0 in Q4 2025 for Xilio Therapeutics, down from $3.3 million in the prior quarter.
In the past five years, Change in Accured Expenses ranged from a high of $3.3 million in Q3 2025 to a low of -$6.1 million in Q1 2025.